Investor Presentation

Emcure Ref: EPL/CS/SE/0066/2026 Date: August 06, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Presentation on Unaudited Financial Results for the quarter ended June 30, 2026. Please find enclosed the presentation on the Unaudited Financial Results for the quarter ended June 30, 2026. The same is also available on the Company’s website i.e., www.emcure.com. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership Number: A25687 Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Results Q1FY27 Aug 06, 2026 39 Disclaimer 127 Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute “forward-looking statements.” These statements are based on Emcure Pharmaceuticals Limited’s current expectations, assumptions, and 155 projections about future events. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that 159 may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such statements may include, but are not limited to, references to Emcure’s business strategy, expansion plans, R&D pipeline, regulatory developments, financial performance, operational efficiencies, market conditions, and other future events. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “may,” “will,” “should,” and similar expressions are intended to identify forward-looking statements. 232 These risks and uncertainties include regulatory changes, competitive pressures, technology changes, supply chain challenges, currency 230 fluctuations, ability to obtain or maintain approvals, product commercialization timelines, and other risks inherent to the pharmaceutical industry. This presentation is for general information only and does not constitute an offer, invitation, solicitation, or recommendation to buy, sell, or subscribe to any securities of Emcure Pharmaceuticals Limited. Product information, including molecules under development or awaiting approval, is for representation purposes only. Availability of products may vary by geography depending on regulatory approvals and patent status. This presentation is not intended to provide medical advice. The Company does not undertake to update or revise any forward-looking statements based on new information or future events. Q1 FY27 – Corporate Updates Mr. Satish Mehta to take over as Chairman, in addition to his existing role as Managing Director & CEO (post the conclusion of the upcoming AGM) Mr. Samit Mehta appointed COO of Emcure Pharmaceuticals 241 ▪ Gets broader oversight of the Group’s R&D, operations and licensing activities. 241 ▪ The elevation strengthens Emcure’s leadership and reinforces continuity in promoter-family stewardship Gennova Biopharmaceuticals, now a wholly-owned subsidiary ▪ Mr. Samit Mehta to lead as CEO 73 ▪ Will continue to anchor the Group's biologics and biosimilars capabilities ▪ Will complement Emcure's broader R&D and pipeline priorities These steps strengthen the institutional depth required to deliver our five-year plan and create enduring value over the long term Q1 FY27 - Key Financial Snapshot Key Highlights – Q1FY27 155 ▪ Strong all-round performance with increased Revenue / Growth EBITDA / Margin PAT / Margin 159 contribution from the International business (58%) ▪ International Business revenue up 34.2% YoY with 25,804 / 22.8% 5,080 / 19.7% 2,925 / 11.3% strong growth across Europe, RoW and Canada 241 50 bps 110 bps ▪ Domestic revenue growth at 10.2%, reflecting a 241 Revenue (INR Mn) / YoY growth EBITDA (INR Mn) / Margin PAT (INR Mn) / Margin resilient performance 252 ▪ Productivity gains and operating leverage help 232 improve EBITDA margin by 50 bps ▪ PAT margin up 110 bps, at 11.3% - underline the Segment Revenue Mix – Q1FY27 strength of the quarter’s operating performance. Domestic — 42% International — 58% 42% 20% 21% 17% India RoW EU CA Q1FY27 – Other Financial Data Points R&D (INR Mn) RoCE1 R&D as % 3.6% 4.2% 3.5% 3.5% of Revenue 23.7% 23.4% 159 3,835 22.0% 2,875 241 730 904 241 FY25 FY26 Q1FY26 Q1FY27 31-Mar-2025 31-Mar-2026 30-Jun-2026 CAPEX (INR Mn) Net debt (INR Mn) Net debt to TTM2 0.3 0.7 0.6 1 EBITDA (x) 73 4,342 10,538 11,026 3,763 4,883 1,168 FY25 FY26 Q1FY26 Q1FY27 31-Mar-2025 31-Mar-2026 30-Jun-2026 1RoCE refers to Return on Capital Employed, and is calculated by dividing EBIT for a given year by Capital Employed (i.e., total equity plus Net Debt) as of the end of that year; 2TTM: Trailing twelve months Q1 FY27 – Domestic Business Performance Domestic (INR Mn) Key Highlights ▪ Performance in line with expectations, supported by 40,270 normalized Zuventus performance. 36,597 ▪ Growth across CNS, women’s health franchise and cardio- metabolics range led by key brands like Tenectase, Orofer XT, Orofer FCM, Metpure, etc. and supported by the Sanofi OAD and Roche portfolio 10,953 9,935 ▪ Improved share of chronic segment FY25 FY26 Q1FY26 Q1FY27 ▪ Continue to build Poviztra® uptake; recent MASH1 indication to help expand beyond traditional cardio-metabolics franchise ▪ Continued productivity enhancement reflected in increasing PCPM Expect continued growth over the full year as our strengthened team and portfolio gain traction 1MASH– Metabolic dysfunction-associated steatohepatitis Q1 FY27 – International Business Performance 138 Europe (INR Mn) Canada (INR Mn) RoW (INR Mn) 18,498 14,869 18,399 155 14,738 12,520 15,105 5,367 4,266 5,218 4,042 3,425 3,603 241 FY25 FY26 Q1FY26 Q1FY27 FY25 FY26 Q1FY26 Q1FY27 FY25 FY26 Q1FY26 Q1FY27 ARV1 252 ▪ Strong EU and steady U.K. performance led ▪ Healthy growth through market share gains ▪ Strong orderbook led performance 232 by continued base business execution and new launches 230 ▪ Liposomal Amphotericin B contribution ▪ Growth balanced in both Quebec and rest of ▪ Signed a royalty-free, non-exclusive voluntary licensing agreement with MSD for alimatravir, continues to grow the Canada markets a once-monthly oral PrEP² candidate, currently ▪ Product pipeline provides continued ▪ Received one product approval and in late-stage development visibility for sustained growth over the launched two new products 125 Non-ARV1 medium term ▪ Scaling up of in-house developed portfolio across key markets ▪ 15+ products approved across Asia, Africa and LATAM in Q1 FY27; expanded into 3 new territories A well diversified international platform driven by sustained business performance across both the base business and new business opportunities 1ARV – Anti retroviral , 2 PrEP - Pre-exposure prophylaxis 39 P&L Summary | Q1 FY27 INR Mn except % Q1 FY27 Q1 FY26 YoY % Q4 FY26 QoQ % FY26 Revenue from Operations 25,804 21,005 22.8% 24,697 4.5% 92,035 Domestic 10,953 9,935 10.2% 9,772 12.1% 40,270 International 14,851 11,070 34.2% 14,925 -0.5% 51,766 RoW 5,218 3,603 44.8% 5,557 -6.1% 18,399 241 EU 5,367 4,042 32.8% 5,376 -0.2% 18,498 CA 4,266 3,425 24.6% 3,992 6.9% 14,869 Gross Profit 15,073 12,985 16.1% 14,666 2.8% 55,465 Gross Profit Margin 58.4% 61.8% 340bps 59.4% 100bps 60.3% 230 EBITDA 5,080 4,039 25.8% 4,855 4.6% 17,886 EBITDA Margin 19.7% 19.2% 50bps 19.7% - 19.4% 73 Profit Before Tax (PBT) 3,935 2,908 35.3% 3,412 15.3% 12,871 Effective Tax Rate (%) 25.7% 26.1% 28.6% 26.9% Profit After Tax (PAT) 2,925 2,148 36.2% 2,437 20.0% 9,413 PAT Margin 11.3% 10.2% 110bps 9.9% 140bps 10.2% Adjusted Pro [Showing first 8,000 characters — download PDF for full document]